Satisfaction with Lung Clearance Index Testing as Compared to Spirometry Performed Before and After Hospitalization for Cystic Fibrosis Pulmonary Exacerbation
Danielle Goetz1*, M. Barbara Howard2, Changxing Ma1, Beth Cahill1, Michelle Westley2, Drucy Borowitz1, Daniel Sheehan1
1Department of Pediatrics, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, USA
2John R. Oishei Children’s Hospital, Buffalo, NY, USA
*Corresponding
author: Danielle Goetz, Department of Pediatrics, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, USA. Tel: +17168293955; Email: dgoetz@upa.chob.edu
Received Date: 29 December, 2017; Accepted Date: 12 January, 2018; Published Date: 23 January, 2018
Abstract
Introduction: Patients with Cystic Fibrosis (CF) have intermittent Pulmonary
Exacerbations (PEx) with increased cough and decreased pulmonary function. Lung
Clearance Index (LCI) measures ventilation inhomogeneity using inert gas or
nitrogen washout. LCI is increased in CF compared to healthy subjects.
LCI decreases after treatment for CF PEx; whereas, forced expiratory
volume in 1 second predicted (FEV1%) increases. Relationships between objective measures (FEV1%, LCI by nitrogen
washout) and qualitative measures (Patient Satisfaction) surrounding treatment
for PEx have not been reported.
Materials and Methods: Subjects > age 7 years, admitted for treatment of PEx, were
recruited. After informed consent/assent, spirometry and LCI (Nitrogen Washout)
were performed at the beginning and end of treatment for PEx. A short
questionnaire evaluated patient satisfaction with LCI and spirometry at both
time points.
Results: Twenty-five patients with CF (9-25 years), performed spirometry
and LCI before and after hospitalization for CF PEx. There was better
satisfaction with LCI compared to PFT, (mean score 1.7 versus 2.8; LCI easier
to perform) (p < 0.01). There was an average decline in LCI of
1.5 units (±1.16, p <0.01); FEV1% increased by 10.1% (± 9.6, p< 0.01). There
was a moderate inverse relationship between mean change in LCI and mean change
in FEV1% predicted (r= - 0.43,
p<0.01).
Conclusion: LCI was well tolerated by people with CF and was perceived to
cause less cough and trouble breathing than spirometry. There was a moderate
inverse correlation between LCI and FEV1%; both tests detect improvement in airways obstruction following
treatment for CF.
Keywords: Cystic Fibrosis; Lung Clearance Index (LCI); Multiple Breath
Washout (MBW); Patient Experience; Patient Satisfaction; Pulmonary Exacerbation
1. Abbreviations:
CF : Cystic Fibrosis
PEX : Pulmonary Exacerbations
LCI : Lung Clearance Index
FEV1% : Forced Expiratory Volume in 1 Second,
Percent Predicted
PFT : Pulmonary Function Test
FEF25-75% : Forced Expiratory Flow Between 25 And 75% Volume, Percent
Predicted
2. Introduction
Cystic Fibrosis (CF) is an inherited disease resulting in
progressive lung damage, including chronic inflammation, endo-bronchial
infection, and bronchiectasis. Pulmonary function tests in people with CF
demonstrate airways obstruction, which over time leads to respiratory failure [1]. Patients with CF have
pulmonary exacerbations (PEx), characterized by periods of increased cough and
sputum production, increased fatigue, malaise and/or weight loss, combined with
decreased pulmonary function [2].
PEx are associated with increased morbidity and mortality and are
generally treated with admission to the hospital for intravenous antibiotics
and increased airway clearance therapies [1,3]. Symptoms usually improve in 1 to 2 weeks, unless lung disease is
severe, and then may take longer. To assess for objective improvement, patients
have lung function tests including spirometry (measuring forced expiratory
flows such as FEV1% and FEF25-75%) before and toward the end of hospitalization.
Spirometry is widely available but requires reliable and repeated
maximal forced expiratory efforts that can lead to coughing and fatigue. It is
rarely used in children under age 6 years because cooperation is needed to
perform the required maneuvers. Since spirometry values are dependent on
height, percent predicted values must be used in growing children.
Lung Clearance Index (LCI) is a lung function test that can
measure ventilation inhomogeneity in the lungs by using the Multiple Breath
Washout (MBW) technique using either nitrogen or another inert gas such as SF6 MBW
measures the number of lung turnovers required to washout an inert gas such as
nitrogen to 1/40th of the starting concentration. A high value indicates
abnormal ventilation distribution. The technique is reproducible and does not
require forced expiratory efforts, thus it can be performed even in young
children [4]. LCI measurements are
not dependent on age, height or gender [5].
They may indicate obstruction even when standard forced maneuvers are in the
normal range [6]. However, in patients
with severe obstruction, the time to clear the inert gas may be prolonged [7].
LCI is increased in people with CF compared to healthy subjects [8,9] and has been shown to
improve (Decrease) after treatment for CF PEx [10]. FEV1% predicted usually improves (Increases) during the same treatment
period [11]. Change in FEV1% is the standard measure
of adequate treatment for PEx but the forced maneuver may cause cough; change
in LCI is not the standard measure of adequate treatment of PEx but may (or may
not) be easier to perform. Patient satisfaction with LCI has been
briefly examined with a two-item questionnaire using the InnocorTM SF6 washout device during a
stable visit, but has not been reported using a nitrogen washout device or
during a period of exacerbation compared to spirometry [9]. We aimed to compare
patient and parent satisfaction with LCI using a nitrogen washout device
compared to standard Pulmonary Function Testing (PFT) and to compare the change
in LCI to the change in FEV1% predicted before and after treatment for CF PEx.
3. Materials and Methods
For this exploratory study, we enrolled a convenience sample of
subjects > age 7 years, consecutively admitted to Women and Children’s
Hospital of Buffalo for treatment of PEx. After informed consent was obtained
(including assent, as indicated) spirometry and LCI (in that order) were
performed by the subjects at the beginning and end of treatment for PEx. Lung
function tests were performed at least in duplicate. If hypertonic saline was
part of the treatment regimen, it was withheld before study pulmonary function
tests because it can exacerbate cough. Nose clips were applied and spirometry
was performed according to American Thoracic Society (ATS) criteria [12]. Satisfaction with
testing was assessed with a four-item questionnaire with a Likert scale for
each test (1= greatest satisfaction, 5= least satisfaction) at the beginning
and end of hospitalization and a mean score was generated (Table 1).
Multiple breath nitrogen washout was performed according to CF
Foundation Therapeutics Development Network standards using N2 MBW with an open
circuit, bias flow system (Exhalyzer D®, EcoMedics AG, and Duernten, Switzerland) and associated software
(Spiroware®3.1 EcoMedics AG) [8].
Basic demographic information was collected. Height, weight and oxygen
saturation were measured and recorded.
4. Statistical Analysis
Continuous variables were summarized using the following
descriptive summary statistics: the number of subjects (n), mean, SD, median,
range; while categorical variables were summarized using counts and
percentages. The change in airways obstruction as measured by calculations of
lung clearance index measured at the start and end of hospitalization with
intravenous antibiotic treatment for pulmonary exacerbation of CF was tested by
paired t-test.
Pearson’s correlation was used to compare the change in LCI versus
the change in FEV1%, FEF25-75% predicted and specific conductance, respectively, before and
after hospitalization for treatment of CF PEx. Patient satisfaction with use of
spirometry and multiple breath washout for measurement of lung clearance index
was summarized by counts and percentages. All analysis was carried out by SAS
9.3 (Cary, NC).
5. Results
Between August 2014 and October 2015, 25 patients with CF (9-25
years) were enrolled (64% female). Thirty-nine percent were F508del homozygotes
and 48% were F508del heterozygotes; 57% grew Pseudomonas and 39% grew MRSA in
sputum cultures. There were 23 unique subjects in the study (2 consented during
2 different hospitalizations), and 21 complete data sets. One subject withdrew
consent before testing, one withdrew due to sinus pain after one LCI maneuver.
Two subjects performed LCI at the beginning but not at end of hospitalization;
their satisfaction data was still counted (one had vomiting before discharge
test maneuvers and one did not want to participate in the discharge test
because she was anxious to be discharged). The mean time between tests was 8.7
days (range 5-15 days).
There was better satisfaction with LCI as compared to PFT,
(average mean score 1.7 compared to 2.8 before hospitalization, and 1.6
compared to 2.1 after hospitalization (Figure 1), respectively, indicating greater ease of performing test (p <
0.01). Patients reported less cough and trouble breathing with performing
LCI as compared to PFT (questions # 2 and 3, respectively).
Compared to values obtained at the start of treatment for a PEx,
there was an average decline in LCI of 1.5 units (± 1.16, p <0.01) (see Figure 2a) and an increase in FEV1% predicted of 10.1% (± 9.6, p< 0.01) (Figure 2b). In 17 of the 21
complete data sets, there was a decrease in LCI and an increase in FEV1% predicted. In two
cases, both LCI and FEV1% predicted increased slightly. In the other two cases, LCI
decreased significantly (-1.19 and -2.23) but the FEV1% predicted decreased by
an insignificant amount (3%).
There was a moderate inverse relationship between mean change in
LCI and mean change in FEV1% predicted (r= - 0.43, p<0.01) (Figure 3). The change in FEF25-75% was not significant and there was no significant relationship
between change in LCI and change in FEF25-75%.
6. Discussion
In 2001 the Institute of Medicine published “Crossing the Quality
Chasm”, setting principles for improved care delivery. One key principle
emphasized that services delivered should be patient- centered [13]. Although the patient
perception of the quality of inpatient and outpatient care frequently is
measured with satisfaction surveys, there are very few studies assessing
patient preference with performance of diagnostic testing. In one example, if
diagnostic tests are equivalent, patients prefer collection of saliva or urine
over blood [14]. Lung function testing
can cause coughing and dyspnea, especially at the onset of a pulmonary
exacerbation of CF. LCI was well tolerated in the study and was more acceptable
for ease of performance in CF patients who were admitted for PEx. Of note, this
was true at the end of treatment as well as at the beginning of treatment for
PEx even though spirometry is less likely to cause distress once the
obstruction, infection and inflammation of PEx has been treated.
LCI values above 6.5 to 7 indicate abnormal ventilation
distribution. Recently, LCI has been used to measure small airways dysfunction
in children with Cystic Fibrosis (CF) who may have normal values or minimal
abnormalities using standard spirometry [15]. LCI has been used to identify PEx in children [16]. We report a moderate
inverse relationship between spirometry and LCI; LCI decreased while FEV1%
predicted increased during hospitalization for CF PEx, as would be expected if
LCI is a sensitive measure of obstruction. Of note, this inverse correlation in
FEV1% predicted and LCI is
not always seen [17]. Similarly, we saw a discordance in FEV1% and LCI in 4 out of 21
data sets.
Equipment now available for LCI research has overcome prior
constraints of size, cost and lack of commercial availability. In research
subjects who are younger or who have normal FEV1%, this test is
especially helpful as an efficacy endpoint [18,19]. Another research team has shown that shorter washout periods
with this system may be sufficient in children [20]. Limitations of this study include that in all cases, spirometry
was performed before LCI with a short 5-10-minute break in between. This was
done because priority was given to the clinical test in case the patient was
too tired or unable to complete the entire testing episode. It is thought that
the spirometry did not significantly impact the results of the LCI. Other
studies have demonstrated there is not a significant impact of forced
expiratory maneuvers on LCI results [9].
However, it is possible that the forced maneuvers led to cough clearance that
made LCI less likely to cause cough. The satisfaction score we used was not
validated, but it was easy to complete and directly applicable to the questions
we hoped to explore. The sample size was relatively
small and was from one institution, but still contributes to the
experience needed with LCI for use in research studies across the country that
was mentioned in a Cystic Fibrosis Foundation Workshop report [8].
7. Conclusions
Our data indicate that LCI testing was well tolerated by children
and young adults with CF and was perceived to cause less cough and trouble
breathing than standard PFT. We found a moderate inverse correlation between
LCI and FEV1% suggesting that both tests detect improvement in airways
obstruction following treatment for pulmonary exacerbation of CF. Patient
preference and acceptance should be part of the assessment of any new
diagnostic test.
Question 1: This test was hard to do |
Question 2: This test made me cough. |
Question 3: I had trouble breathing during this test. |
Question 4: I would have trouble doing this test again. |
Table 1: Four- Item Questionnaire for Assessment of Patient Satisfaction with Regular Pulmonary Function Test (PFT) and for LCI. Each question was answered on a Likert scale: (1=Strongly Disagree, 2= Disagree, 3= Neutral, 4= Agree, 5= Strongly agree). A mean score was generated for PFT and for LCI before and after hospitalization.
- Ferkol T, Rosenfeld M, Milla C (2006) Cystic
fibrosis pulmonary exacerbations. J Pediatr 148: 259-264.
- Kraynack NC, Gothard MD, Falletta LM, McBride JT (2011) Approach to treating cystic fibrosis pulmonary exacerbations varies widely across US CF care centers. Pediatr Pulmonol 46: 870-881.
- VanDevanter DR, Elkin EP, Pasta DJ, Morgan WJ, Konstan MW (2013) For the Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis. Changing thresholds and incidence of antibiotic treatment of cystic fibrosis pulmonary exacerbations. J Cyst Fibros12: 332-337.
- Robinson PD, Godman MD, Gustafsson PM (2009) Inert gas washout: theoretical background and clinical utility in respiratory disease. Respiration 78: 339-355.
- Horsley AR, Gustafsson PM, Macleod KA, Saunders C, Greening AP, et al. (2008) Lung clearance index is a sensitive, repeatable and practical measure of airways disease in adults with cystic fibrosis. Thorax 63: 135-140.
- Kraemer R, Blum A, Schibler A, Ammann RA, Gallati S. Ventilation in homogeneities in relation to standard lung function in patients with cystic fibrosis. Am J Respir Crit Care Med 171: 371-378.
- Horsely A and Wild JM (2015) Ventilation heterogeneity and the benefits and challenges of multiple breath washout testing in patients with cystic fibrosis. Paediatric Respiratory Reviews 16S 15-18.
- Subbarao P, Milla C, Aurora P, Davies JC, Davis SD, et al. (2015) Multiple-Breath Washout as a lung function test in Cystic Fibrosis. A Cystic Fibrosis Foundation Workshop Report. Ann Am Thorac Soc 12: 932-939.
- O'Neill K, Tunney MM, Johnston E, Rowan S, Downey DG, et al. (2016) Lung clearance index in adults and children with cystic fibrosis. Chest 150: 1323-1332.
- Robinson PD, Cooper P, Asperren PV, Fitzgerald D, Selvadurai H (2009) Using index of ventilation to assess response to treatment for acute pulmonary exacerbation in children with cystic fibrosis. Pediatr Pulmonol 44: 733-742.
- Horsley AR, Davies JC, Gray RD, Macleod KA, Donovan J, et al. (2013) Changes in physiological, function and structural markers of cystic fibrosis lung disease with treatment of a pulmonary exacerbation. Thorax 68: 532-539.
- Miller MR, Hankinson J, Brusasco V, F. Burgos, R. Casaburi, et al. (2005) Standardisation of spirometry, Series “ATS/ERS Task Force: Standardisation of Lung Function Testing” Eur Respir J 26: 319-338.
- Committee on Quality Health Care in America, Institute of Medicine. Crossing the Quality Chasm: a New Health System for the 21st Century. Washington, D.C: National Academy Press, 2001; Qual Lett Healthc Lead 13: 14-15.
- Koka S, Beebe TJ, Merry SP, DeJesus RS, Berlanga LD, et al. (2008) The preferences of adult outpatients in medical or dental care settings for giving saliva, urine or blood for clinical testing. J Am Dent Assoc 139: 735-740.
- Ellemunter H, Fuchs SI, Unsinn KM, Freund MC, Waltner-Romen M, et al. (2010) Sensitivity of lung clearance index and chest computed tomography in early cystic fibrosis lung disease. Respiratory Medicine 104: 1834-1842.
- Vermeulen F, Proesmans M, Boon M, Havermans T, De Boeck K (2014) Lung clearance index predicts pulmonary exacerbations in young patients with cystic fibrosis. Thorax 69: 39-45.
- Sonneveld N, Stanojevic S, Amin R, Aurora P, Davies J, et al. (2015) Lung clearance index in cystic fibrosis subjects treated for pulmonary exacerbations. Eur Respir J 46: 1055.
- Amin R, Subbarao P, Lou W, Jabar A, Balkovec S, et al. (2011) The effect of dornase alfa on ventilation inhomogeneity in patients with cystic fibrosis. Eur Respir J 37: 806-812.